Gilliland Jeter Wealth Management LLC Invests $986,000 in IQVIA Holdings Inc. (NYSE:IQV)

Gilliland Jeter Wealth Management LLC acquired a new position in IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 4,262 shares of the medical research company’s stock, valued at approximately $986,000.

A number of other institutional investors and hedge funds also recently modified their holdings of IQV. AdvisorNet Financial Inc increased its position in shares of IQVIA by 327.6% during the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 95 shares during the last quarter. BKM Wealth Management LLC purchased a new stake in shares of IQVIA during the fourth quarter valued at approximately $32,000. Activest Wealth Management purchased a new stake in shares of IQVIA during the fourth quarter valued at approximately $35,000. CVA Family Office LLC purchased a new stake in IQVIA in the fourth quarter worth $43,000. Finally, CoreFirst Bank & Trust purchased a new stake in IQVIA in the third quarter worth $44,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of recent research reports. SVB Leerink initiated coverage on IQVIA in a research report on Monday, February 26th. They issued an “outperform” rating and a $290.00 target price for the company. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. Robert W. Baird raised their target price on IQVIA from $226.00 to $251.00 and gave the stock a “neutral” rating in a research report on Thursday, February 15th. Evercore ISI raised their target price on IQVIA from $255.00 to $265.00 and gave the stock a “market outperform” rating in a research report on Thursday, February 15th. Finally, Leerink Partnrs reissued an “outperform” rating on shares of IQVIA in a research report on Monday, February 26th. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $256.80.

IQVIA Price Performance

NYSE:IQV traded up $0.90 during trading hours on Friday, hitting $234.88. 697,640 shares of the company’s stock traded hands, compared to its average volume of 761,918. The firm has a market cap of $42.63 billion, a P/E ratio of 32.22, a P/E/G ratio of 2.27 and a beta of 1.50. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73. The business’s fifty day simple moving average is $245.28 and its two-hundred day simple moving average is $223.17. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.82 by $0.02. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The company had revenue of $3.87 billion during the quarter, compared to analyst estimates of $3.80 billion. During the same quarter last year, the company earned $2.54 earnings per share. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.12 earnings per share for the current fiscal year.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the sale, the insider now owns 5,251 shares in the company, valued at $1,313,642.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the transaction, the insider now owns 796,752 shares in the company, valued at $199,610,278.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Kevin C. Knightly sold 8,607 shares of IQVIA stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the transaction, the insider now owns 5,251 shares in the company, valued at approximately $1,313,642.67. The disclosure for this sale can be found here. Insiders have sold 41,285 shares of company stock worth $10,331,003 over the last 90 days. Corporate insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.